Caenorhabditis elegansSEL-5/AAK1 regulates cell migration and cell outgrowth independently of its kinase activity DOI Creative Commons
Filip Knop,

Apolena Zounarová,

Vojtěch Šabata

и другие.

bioRxiv (Cold Spring Harbor Laboratory), Год журнала: 2023, Номер unknown

Опубликована: Март 30, 2023

Abstract During Caenorhabditis elegans development multiple cells migrate long distances or extend processes to reach their final position and/or attain proper shape. Wnt signalling pathway stands out as one of the major coordinators cell migration outgrowth along anterior-posterior body axis. outcome is fine-tuned by various mechanisms including endocytosis. In this study, we show that SEL-5, C. orthologue mammalian AP2-associated kinase AAK1, acts together with retromer complex a positive regulator EGL-20/Wnt during QL neuroblast daughter cells. At same time, SEL-5 in cooperation also required excretory canal outgrowth. Importantly, activity not for its role either neuronal and neither these dependent on DPY-23/AP2M1 phosphorylation. We further establish proteins CWN-1 CWN-2 Frizzled receptor CFZ-2 positively regulate outgrowth, while LIN-44/Wnt LIN-17/Frizzled generate stop signal inhibiting extension.

Язык: Английский

Strategies of Targeting CK2 in Drug Discovery: Challenges, Opportunities, and Emerging Prospects DOI

Yijia Chen,

Yuxi Wang, Jiaxing Wang

и другие.

Journal of Medicinal Chemistry, Год журнала: 2023, Номер 66(4), С. 2257 - 2281

Опубликована: Фев. 6, 2023

CK2 (casein kinase 2) is a serine/threonine protein that ubiquitous in eukaryotic cells and plays important roles variety of cellular functions, including cell growth, apoptosis, circadian rhythms, DNA damage repair, transcription, translation. involved cancer pathogenesis the occurrence many diseases. Therefore, targeting promising therapeutic strategy. Although CK2-specific small-molecule inhibitors have been developed, only CX-4945 has progressed to clinical trials. In recent years, novel gradually become research hotspot, which expected overcome limitations traditional inhibitors. Herein, we summarize structure, biological disease relevance emphatically analyze structure-activity relationship (SAR) binding modes We also discuss latest progress strategies, providing insights into new drugs for practice.

Язык: Английский

Процитировано

42

Strategies of targeting CYP51 for IFIs therapy: Emerging prospects, opportunities and challenges DOI
Ruofei Zhang, Yuxi Wang,

Aijia Wu

и другие.

European Journal of Medicinal Chemistry, Год журнала: 2023, Номер 259, С. 115658 - 115658

Опубликована: Июль 17, 2023

Язык: Английский

Процитировано

22

Small molecule LpxC inhibitors against gram-negative bacteria: Advances and future perspectives DOI
Zhendong Niu,

Peng Lei,

Yuxi Wang

и другие.

European Journal of Medicinal Chemistry, Год журнала: 2023, Номер 253, С. 115326 - 115326

Опубликована: Март 31, 2023

Язык: Английский

Процитировано

20

Targeting HSP90 for Cancer Therapy: Current Progress and Emerging Prospects DOI

Xinqi Liang,

Ruixian Chen, Chengdi Wang

и другие.

Journal of Medicinal Chemistry, Год журнала: 2024, Номер 67(18), С. 15968 - 15995

Опубликована: Сен. 11, 2024

Heat shock protein 90 (HSP90), a highly conserved member of the heat family, regulates various proteins and signaling pathways involved in cancer, making it promising target for cancer therapy. Traditional HSP90 inhibitors have demonstrated significant antitumor potential preclinical trials, with over 20 compounds advancing to clinical trials showing results. However, limited efficacy shared toxicity these restrict their further use. Encouragingly, developing novel using conventional medicinal chemistry approaches─such as selective inhibitors, dual protein-protein interaction proteolysis-targeting chimeras─is expected address challenges. Notably, inhibitor TAS-116 has already been successfully marketed. In this Perspective, we summarize structure, biological functions, roles analyze status highlight latest advancements strategies, offering insights into future development.

Язык: Английский

Процитировано

8

Recent progress in discovery of novel AAK1 inhibitors: from pain therapy to potential anti-viral agents DOI Creative Commons

Yinghui Yuan,

Nian‐Dong Mao,

Ji‐Long Duan

и другие.

Journal of Enzyme Inhibition and Medicinal Chemistry, Год журнала: 2023, Номер 38(1)

Опубликована: Ноя. 13, 2023

Adaptor associated kinase 1 (AAK1), a member of the Ark1/Prk1 family Ser/Thr kinases, is specific key regulating Thr156 phosphorylation at μ2 subunit adapter complex-2 (AP-2) protein. Due to their important biological functions, AAK1 systems have been validated in clinics for neuropathic pain therapy, and are being explored as potential therapeutic targets diseases caused by various viruses such Hepatitis C (HCV), Dengue, Ebola, COVID-19 amyotrophic lateral sclerosis (ALS). Centreing on advances drug discovery programs this field up 2023, inhibitors discussed from aspects structure-based rational molecular design, pharmacology, toxicology synthetic routes compounds interest review. The aim provide medicinal chemistry community with up-to-date information accelerate small molecule inhibitors.

Язык: Английский

Процитировано

12

Research progress of DDR1 inhibitors in the treatment of multiple human diseases DOI
Mengying Liu, Jifa Zhang, Xiaoxue Li

и другие.

European Journal of Medicinal Chemistry, Год журнала: 2024, Номер 268, С. 116291 - 116291

Опубликована: Фев. 27, 2024

Язык: Английский

Процитировано

5

Technologies of targeting histone deacetylase in drug discovery: Current progress and emerging prospects DOI

Jinxiao Ru,

Yuxi Wang, Zijia Li

и другие.

European Journal of Medicinal Chemistry, Год журнала: 2023, Номер 261, С. 115800 - 115800

Опубликована: Сен. 9, 2023

Язык: Английский

Процитировано

10

An amino-rich polymer-coated magnetic nanomaterial for ultra-rapid separation of phosphorylated peptides in the serum of Parkinson’s disease patients DOI
Xiaoya Zhang, Bing Wang,

Yiting Luo

и другие.

Analytical and Bioanalytical Chemistry, Год журнала: 2024, Номер 416(14), С. 3361 - 3371

Опубликована: Апрель 12, 2024

Язык: Английский

Процитировано

3

Analysis of miRNAs in milk of four livestock species DOI Creative Commons
Filippo Cendron, Umberto Rosani, Marco Franzoi

и другие.

BMC Genomics, Год журнала: 2024, Номер 25(1)

Опубликована: Сен. 14, 2024

Язык: Английский

Процитировано

3

Development and therapeutic perspectives of CXCR4 antagonists for disease therapy DOI
Jun Yang, Erkang Tian, Li Chen

и другие.

European Journal of Medicinal Chemistry, Год журнала: 2024, Номер 275, С. 116594 - 116594

Опубликована: Июнь 11, 2024

Язык: Английский

Процитировано

2